RESUMO
Purpose@#This study was conducted to identify the effects of a lifestyle intervention program on weight gain, dietary habits, fatigue andpregnancy stress, blood pressure, and neonatal birth weight, using Cox’s interaction model of client health behavior for overweight andobese women. @*Methods@#This was a quasi-experimental research with a non-equivalent control group pre-post test design. A total of 52patients who met the selection criteria, including 25 in the experimental group and 27 in the control group, were the subjects of the study;they comprised overweight and obese pregnant women who were receiving prenatal care at A and B women’s hospital in J province. Thelifestyle intervention program ran for 12 weeks in total and consisted of interactions involving affective support, health information, andprofessional/technical competencies. The data collection period was from February 1, 2017 to August 31, 2017. @*Results@#This study showeddifferences in the appropriate weight gain rate (x2=6.17, p=.013), suppression of an increase in fatigue (t=-2.32, pp =.012), and an increasein pregnancy stress (t=-1.87, p=.034). Yet, no differences in physical activity, dietary habits change, blood pressure, and neonatal birthweight (p>.05) were found. @*Conclusion@#The study findings indicate that this program could be an effective intervention for the control ofappropriate weight gain, fatigue, and pregnancy stress. Therefore, a lifestyle intervention program based on Cox’s interaction model of clienthealth behavior could be an efficient strategy for a positive health outcome of overweight and obesity pregnant women.
RESUMO
No abstract available.
RESUMO
Statins, HMG-CoA reductase inhibitors, are known to cause serious muscle injuries (e.g. myopathy, myositis and rhabdomyolysis), and these adverse effects can be rescued by co-administration of coenzyme Q10 (CoQ10) with statins. The goal of the current research is to assess the efficacy of combined treatment of CoQ10 with Atorvastatin for hyperlipidemia induced by high-fat diet in SD rats. 4-week-old Sprague-Dawley male rats were fed normal diet or high-fat diet for 6 weeks. Then, rats were treated with either Statin or Statin with various dosages of CoQ10 (30, 90 or 270 mg/kg/day, p.o.) for another 6 weeks. Compared to Statin only-treatment, CoQ10 supplementation significantly reduced creatine kinase and aspartate aminotransferase levels in serum which are markers for myopathy. Moreover, CoQ10 supplementation with Statin further reduced total fat, triglycerides, total cholesterol, and low-density lipoprotein-cholesterol. In contrast, the levels of high-density lipoprotein-cholesterol and CoQ10 were increased in the CoQ10 co-treated group. These results indicate that CoQ10 treatment not only reduces the side effects of Statin, but also has an anti-obesity effect. Therefore an intake of supplementary CoQ10 is helpful for solving problem of obese metabolism, so the multiple prescription of CoQ10 makes us think a possibility that can be solved in being contiguous to the obesity problem, a sort of disease of the obese metabolism.
Assuntos
Animais , Humanos , Masculino , Ratos , Aspartato Aminotransferases , Colesterol , Creatina Quinase , Dieta , Dieta Hiperlipídica , Inibidores de Hidroximetilglutaril-CoA Redutases , Hiperlipidemias , Metabolismo , Doenças Musculares , Miosite , Obesidade , Oxirredutases , Prescrições , Ratos Sprague-Dawley , Triglicerídeos , AtorvastatinaRESUMO
Chronic alcohol consumption causes alcoholic liver disease, which is associated with the initiation of dysregulated lipid metabolism. Recent evidences suggest that dysregulated cholesterol metabolism plays an important role in the pathogenesis of alcoholic fatty liver disease. Ecklonia stolonifera (ES), a perennial brown marine alga that belongs to the family Laminariaceae, is rich in phlorotannins. Many studies have indicated that ES has extensive pharmacological effects, such as antioxidative, hepatoprotective, and antiinflammatory effects. However, only a few studies have investigated the protective effect of ES in alcoholic fatty liver. Male Sprague-Dawley rats were randomly divided into normal diet (ND) (fed a normal diet for 10 weeks) and ethanol diet (ED) groups. Rats in the ED group were fed a Lieber-DeCarli liquid diet (containing 5% ethanol) for 10 weeks and administered ES extract (50, 100, or 200 mg/kg/day), silymarin (100 mg/kg/day), or no treatment for 4 weeks. Each treatment group comprised of eight rats. The supplementation with ES resulted in decreased serum levels of triglycerides (TGs), total cholesterol, alanine aminotransferase, and aspartate aminotransferase. In addition, there were decreases in hepatic lipid and malondialdehyde levels. Changes in liver histology, as analyzed by Oil Red O staining, showed that the ES treatment suppressed adipogenesis. In addition, the ES treatment increased the expression of fatty acid oxidation-related genes (e.g., PPAR-α and CPT-1) but decreased the expression of SREBP 1, which is a TG synthesis-related gene. These results suggest that ES extract may be useful in preventing fatty acid oxidation and reducing lipogenesis in ethanol-induced fatty liver.